Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Real-World Data and Lymphoma

Much of the existing data on lymphoma outcomes are derived from RCTs, where the trial protocol determines patient selection and management.

A need remains to collect and analyze real-world data from patients treated outside of clinical trials to verify that these results are being replicated in the real-world setting.

View overview page
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
3:19
How has CAR-T changed survival outcomes in DLBCL so far?
Peter Vandenberghe • 17 Feb 2024
6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
1:19
Real-world outcomes of liso-cel therapy in R/R DLBCL
Peter Riedell • 11 Dec 2023
2:12
The impact of pre-existing autoimmune disease on safety & efficacy of CAR-T for non-Hodgkin lymphoma
Charles Gaulin • 11 Dec 2023
1:24
Real-world outcomes of patients with BV and anti-PD-1 intolerant cHL: the impact of alloSCT & CAR-T
Timothy Voorhees • 10 Dec 2023
8:57
Outcomes of SCT in T-ALL and T-LBL
Yuho Najima • 11 Dec 2023
1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023
2:22
Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo • 10 Dec 2023
3:03
Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo • 10 Dec 2023
4:40
Engraftment syndrome following ASCT in patients with checkpoint inhibitor treated Hodgkin lymphoma
Jakub Svoboda • 11 Dec 2023
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:44
Indirect comparison of brexu-cel versus SOC in R/R MCL
Georg Hess • 20 Oct 2023
1:41
Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selection
Jason Westin • 8 Sep 2023
The content of VJHemOnc is intended for healthcare professionals